GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease: Randomized, placebo-controlled double-blinded clinical trial

M. Gejl; L. Egejord; A. Møller; S. B. Hansen; K. Vang; A. Rodell; H. Brændgaard; H. Gottrup; A. Schacht; N. Møller; B. Brock; J. Rungby; A. Gjedde

doi:10.1007/s00259-015-3198-z

GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease: Randomized, placebo-controlled double-blinded clinical trial

M. Gejl, L. Egejord, A. Møller, S. B. Hansen, K. Vang, A. Rodell, H. Brændgaard, H. Gottrup, A. Schacht, N. Møller, B. Brock, J. Rungby, A. Gjedde

Institut for Neurovidenskab

Originalsprog	Engelsk
Artikelnummer	OP322
Tidsskrift	European Journal of Nuclear Medicine and Molecular Imaging
Vol/bind	42
Udgave nummer	Suppl 1
Antal sider	2
ISSN	1619-7070
DOI	https://doi.org/10.1007/s00259-015-3198-z
Status	Udgivet - 2015

Adgang til dokumentet

10.1007/s00259-015-3198-z

Citationsformater

Gejl, M., Egejord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., Møller, N., Brock, B., Rungby, J., & Gjedde, A. (2015). GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease: Randomized, placebo-controlled double-blinded clinical trial. European Journal of Nuclear Medicine and Molecular Imaging, 42(Suppl 1), [OP322]. https://doi.org/10.1007/s00259-015-3198-z

GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease : Randomized, placebo-controlled double-blinded clinical trial. / Gejl, M.; Egejord, L.; Møller, A. et al.

I: European Journal of Nuclear Medicine and Molecular Imaging, Bind 42, Nr. Suppl 1, OP322, 2015.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Gejl, M, Egejord, L, Møller, A, Hansen, SB, Vang, K, Rodell, A, Brændgaard, H, Gottrup, H, Schacht, A, Møller, N, Brock, B, Rungby, J & Gjedde, A 2015, 'GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease: Randomized, placebo-controlled double-blinded clinical trial', European Journal of Nuclear Medicine and Molecular Imaging, bind 42, nr. Suppl 1, OP322. https://doi.org/10.1007/s00259-015-3198-z

@article{8b4ed3562a3b4eb8921684165147f424,

title = "GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer{\textquoteright}s Disease: Randomized, placebo-controlled double-blinded clinical trial",

author = "M. Gejl and L. Egejord and A. M{\o}ller and Hansen, {S. B.} and K. Vang and A. Rodell and H. Br{\ae}ndgaard and H. Gottrup and A. Schacht and N. M{\o}ller and B. Brock and J. Rungby and A. Gjedde",

year = "2015",

doi = "10.1007/s00259-015-3198-z",

language = "English",

volume = "42",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "Suppl 1",

}

TY - ABST

T1 - GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease

T2 - Randomized, placebo-controlled double-blinded clinical trial

AU - Gejl, M.

AU - Egejord, L.

AU - Møller, A.

AU - Hansen, S. B.

AU - Vang, K.

AU - Rodell, A.

AU - Brændgaard, H.

AU - Gottrup, H.

AU - Schacht, A.

AU - Møller, N.

AU - Brock, B.

AU - Rungby, J.

AU - Gjedde, A.

PY - 2015

Y1 - 2015

U2 - 10.1007/s00259-015-3198-z

DO - 10.1007/s00259-015-3198-z

M3 - Conference abstract in journal

SN - 1619-7070

VL - 42

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - Suppl 1

M1 - OP322

ER -